The "Drug Overview: Zyprexa" report has been added to ResearchAndMarkets.com's offering.
Zyprexa (Eli Lilly) contains the atypical antipsychotic olanzapine, which acts as an antagonist at the D2 and 5-HT2A receptors. Zyprexa was initially launched in September 1996 for the treatment of schizophrenia. Eli Lilly subsequently pursued development in bipolar disorder and received the first approval for Zyprexa as a monotherapy in the treatment of manic and mixed episodes in 2000.
Key Topics Covered
- Drug Overview
- Product Profiles
- Zyprexa: Bipolar Disorder
- Zyprexa: Schizophrenia
List of Figures
Figure 1: Zyprexa for bipolar disorder - SWOT analysis
Figure 2: Drug assessment summary for Zyprexa in bipolar disorder
Figure 3: Drug assessment summary for Zyprexa in bipolar disorder
Figure 4: Zyprexa for schizophrenia - SWOT analysis
Figure 5: Drug assessment summary of Zyprexa for schizophrenia
Figure 6: Drug assessment summary of Zyprexa for schizophrenia
Figure 7: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Zyprexa bipolar disorder indication approvals
Table 2: Zyprexa drug profile
Table 3: Overview of key pivotal trial data for Zyprexa in bipolar disorder
Table 4: Adverse reactions reported in =5% of patients in six-week clinical trials of Zyprexa as an adjunct to lithium or valproate in adult bipolar disorder (manic/mixed episodes)
Table 5: Key side effects reported in clinical trials of Zyprexa in bipolar disorder
Table 6: Zyprexa drug profile
Table 7: Zyprexa pivotal trial data in schizophrenia
Table 8: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country M, 2017-26
For more information about this report visit https://www.researchandmarkets.com/research/hhmvmg/zyprexa_eli?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180511005744/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.